Mylan snags Merck's generic business

May 21, 2007

Mylan Laboratories will become the third-largest generic drug company in the world (behind Teva and Novartis) after signing a definitive agreement under which it will acquire Merck's generic business in a deal worth $6.7 billion.

Mylan Laboratories will become the third-largest generic drug company in the world (behind Teva and Novartis) after signing a definitive agreement under which it will acquire Merck's generic business in a deal worth $6.7 billion. Industry observers noted that the acquisition will place Mylan in the number three slot behind Teva and Novartis with a significant presence in all of the top five global generic markets.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.